5/30
04:30 pm
dnth
Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference
Low
Report
Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference
5/22
08:08 am
dnth
Oruka Therapeutics Expands Leadership Team with Appointment of Industry Veterans Drs. Joseph Senn and Rajiv Panwar [Yahoo! Finance]
Medium
Report
Oruka Therapeutics Expands Leadership Team with Appointment of Industry Veterans Drs. Joseph Senn and Rajiv Panwar [Yahoo! Finance]
5/16
07:32 am
dnth
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $40.00 price target on the stock.
Medium
Report
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $40.00 price target on the stock.
5/10
11:25 am
dnth
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its price target raised by analysts at Wedbush from $33.00 to $38.00. They now have an "outperform" rating on the stock.
Low
Report
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its price target raised by analysts at Wedbush from $33.00 to $38.00. They now have an "outperform" rating on the stock.
5/9
04:01 pm
dnth
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
Low
Report
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
5/8
04:30 pm
dnth
Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference
Medium
Report
Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference
5/3
04:30 pm
dnth
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/25
07:12 am
dnth
Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes Scientific Advisory Board of world-leading experts [Yahoo! Finance]
Low
Report
Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes Scientific Advisory Board of world-leading experts [Yahoo! Finance]
4/18
01:18 pm
dnth
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its price target raised by analysts at Raymond James from $34.00 to $51.00. They now have an "outperform" rating on the stock.
Low
Report
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its price target raised by analysts at Raymond James from $34.00 to $51.00. They now have an "outperform" rating on the stock.
4/11
07:30 am
dnth
Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting
Medium
Report
Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting
4/5
04:30 pm
dnth
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/25
11:53 am
dnth
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its price target raised by analysts at Jefferies Financial Group Inc. from $22.00 to $39.00. They now have a "buy" rating on the stock.
Low
Report
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its price target raised by analysts at Jefferies Financial Group Inc. from $22.00 to $39.00. They now have a "buy" rating on the stock.
3/22
10:24 am
dnth
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its price target raised by analysts at Wedbush from $24.00 to $33.00. They now have an "outperform" rating on the stock.
Medium
Report
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its price target raised by analysts at Wedbush from $24.00 to $33.00. They now have an "outperform" rating on the stock.
3/21
04:14 pm
dnth
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results [Yahoo! Finance]
High
Report
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results [Yahoo! Finance]
3/21
04:01 pm
dnth
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results
High
Report
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results
3/7
04:30 pm
dnth
Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)